6 completed, 6 terminated. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Terminated 4 |
| Phase 1 | 5 | Terminated 3, Completed 2 |
Follow Aduro Biotech, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission GM-CSF vaccine, Lenalidomide, Prevnar13 - Multiple Myeloma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2019-09-23 | 2025-08-27 |
| Safety of ADU-1604 in Adults With Metastatic Melanoma ADU-1604 - Metastatic Melanoma | Phase 1 | Terminated | Aduro Biotech, Inc. | 4 | 2018-11-08 | 2020-05-26 |
| Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer Cyclophosphamide, Nivolumab, Ipilimumab - Pancreatic Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 61 | 2017-12-14 | 2024-08-07 |
| Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers CRS-207, Pembrolizumab - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Terminated | Aduro Biotech, Inc. | 5 | 2017-08-14 | 2019-04-04 |
| Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) CRS-207, Pembrolizumab - Malignant Pleural Mesothelioma | Phase 2 | Terminated | Aduro Biotech, Inc. | 10 | 2017-05-31 | 2019-04-04 |
| Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer pLADD - Colorectal Neoplasms | Phase 1 | Terminated | Aduro Biotech, Inc. | 28 | 2017-05-02 | 2020-10-01 |
| Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer CRS-207, Epacadostat, Pembrolizumab - Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer | Phase 1 / Phase 2 | Terminated | Aduro Biotech, Inc. | 35 | 2016-03-08 | 2019-04-04 |
| GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab CRS-207, nivolumab, GVAX - Previously Treated Metastatic Adenocarcinoma of the Pancreas | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 93 | 2015-01-02 | 2021-04-06 |
| Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy - Malignant Pleural Mesothelioma | Phase 1 | Completed | Aduro Biotech, Inc. | 60 | 2014-09-03 | 2020-09-30 |
| Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting GVAX Pancreas Vaccine, CRS-207, Chemotherapy - 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer | Phase 2 | Completed | Aduro Biotech, Inc. | 303 | 2014-02-05 | 2018-06-04 |
| Phase I Study of Safety and Immunogenicity of ADU-623 Cohort 1, Cohort 2, Cohort 3 - Astrocytic Tumors, Glioblastoma Multiforme | Phase 1 | Completed | Providence Health & Services | 11 | 2014-01-08 | 2018-08-17 |
| Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer GVAX Pancreas, CRS-207, Cyclophosphamide - Metastatic Pancreatic Cancer | Phase 2 | Completed | Aduro Biotech, Inc. | 93 | 2011-09-21 | 2018-05-08 |
Neoplasms (4) · Mesothelioma, Malignant (2) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Esophageal Neoplasms (1) · Gastrointestinal Diseases (1) · Glioblastoma (1) · Melanoma (1) · Multiple Myeloma (1)
Cyclophosphamide (5) · pembrolizumab (3) · Drug Therapy (2) · Nivolumab (2) · Amoxicillin (1) · Amoxicillin-Potassium Clavulanate Combination (1) · Anti-Bacterial Agents (1) · Cisplatin (1) · Immunotherapy (1) · Ipilimumab (1) · KPNA1 protein, human (1) · Lenalidomide (1) · Pemetrexed (1) · Pneumococcal Vaccines (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1)
United States (11) · Canada (2) · France (1) · Spain (1)
Dung Le, MD (2) · Dung T Le, MD (1) · Marka Crittenden, MD, PhD (1) · Raffit Hassan, MD (1) · Syed A Ali, MD (1)
PMID 29997287, PMID 31126960, PMID 31263030
P01CA247886 (1)